MMP14 and neoplasm: identified MMP14 as the key antigen for tumor‐reactive autoantibodies in high‐grade serous ovarian carcinoma, consistent with earlier observations that B‐cell involvement in tumors is associated with favorable patient outcomes [15, 16].